Whole body and intracranial efficacy of ceritinib in ALK-inhibitor (ALKi)-naive patients (pts) with ALK-rearranged (ALK+) NSCLC and baseline (BL) brain metastases (BM): Results from ASCEND-1 and -3.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Vall d'Hebron Institut de Recerca, National Cancer Centre Singapore, Seoul National University Hospital, Fox Chase Cancer Center, Samsung Medical Center, Sungkyunkwan University, National Taiwan University, Chinese University of Hong Kong, Japanese Foundation For Cancer Research, University of Turin, Sarah Cannon, Novartis (United States), Massachusetts General Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2626293156